SG Americas Securities LLC purchased a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) during the 3rd quarter, HoldingsChannel reports. The fund purchased 19,644 shares of the company’s stock, valued at approximately $151,000.
Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Tango Therapeutics by 3.4% in the 1st quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock valued at $24,462,000 after buying an additional 101,673 shares in the last quarter. Artal Group S.A. acquired a new stake in Tango Therapeutics in the 1st quarter valued at $17,427,000. Point72 Asset Management L.P. acquired a new stake in Tango Therapeutics in the 2nd quarter valued at $3,836,000. Dimensional Fund Advisors LP boosted its stake in Tango Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Tango Therapeutics by 110.8% in the fourth quarter. Wellington Management Group LLP now owns 170,228 shares of the company’s stock worth $1,685,000 after purchasing an additional 89,481 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.
Insider Activity
In other news, major shareholder Rock Ventures Iv L.P. Third sold 40,000 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $9.80, for a total transaction of $392,000.00. Following the transaction, the insider now owns 17,486,475 shares of the company’s stock, valued at $171,367,455. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, major shareholder Rock Ventures Iv L.P. Third sold 40,000 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $9.80, for a total value of $392,000.00. Following the completion of the sale, the insider now owns 17,486,475 shares in the company, valued at approximately $171,367,455. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Boxer Capital Management, Llc sold 625,000 shares of the company’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $7.05, for a total value of $4,406,250.00. Following the completion of the sale, the insider now owns 7,573,642 shares of the company’s stock, valued at $53,394,176.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,292,400 shares of company stock valued at $11,528,872 over the last 90 days. 6.20% of the stock is owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Analysis on TNGX
Tango Therapeutics Stock Up 0.3 %
Shares of TNGX opened at $6.29 on Friday. Tango Therapeutics, Inc. has a 12-month low of $6.12 and a 12-month high of $13.01. The firm has a market capitalization of $672.06 million, a PE ratio of -5.57 and a beta of 0.81. The stock’s fifty day simple moving average is $8.79 and its 200-day simple moving average is $8.47.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.10. Tango Therapeutics had a negative return on equity of 44.73% and a negative net margin of 274.04%. The business had revenue of $19.88 million for the quarter, compared to analyst estimates of $7.39 million. Analysts anticipate that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.
Tango Therapeutics Company Profile
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
- Five stocks we like better than Tango Therapeutics
- The 3 Best Blue-Chip Stocks to Buy Now
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How to buy stock: A step-by-step guide for beginners
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Use the MarketBeat Dividend Calculator
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report).
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.